Updated July 2026
Windsor Drake advises founder-led companies outside the United States on sales to U.S. acquirers. A cross-border sale to a U.S. buyer follows the same competitive-process logic as a domestic deal, with added layers: currency, tax treaty structure, regulatory approvals, and the diligence bar a U.S. acquirer applies to a foreign target. Handled well, those layers are manageable; handled late, they cost time and price. Windsor Drake also maintains dedicated resources for Japanese and German technology founders considering a North American sale, available in 日本語, Deutsch, Français and Español.
U.S. strategics and private equity firms acquire abroad to enter markets, add technology and talent, and consolidate fragmented sectors faster than they could organically. For a founder, that means the most motivated and best-capitalized buyer is often American, even when most local advisors only run a domestic process. The premium usually goes to the company that is positioned and presented the way a U.S. acquirer underwrites, not the way a local sale would be packaged.
The spine is a managed, competitive process: preparation and a clean data room, a curated outreach to U.S. strategics and sponsors in parallel, indications of interest, management meetings, letters of intent, then confirmatory diligence and documentation. Competition among credible U.S. buyers is what sets price and terms, the same as any well-run sell-side process.
What differs is the overlay: financials presented to U.S. expectations, cross-border diligence on contracts and IP, currency and treaty-aware structuring, and any required regulatory clearances. A cross-border process typically runs five to eight months, with approvals on the back end the most common source of added time.
The single biggest value driver is making a foreign target feel low-risk to a U.S. buyer. Clean, U.S.-legible financials and transferable contracts narrow the discount a buyer would otherwise apply for cross-border uncertainty.
Cross-border deals can trigger reviews that domestic deals do not: CFIUS in the United States for certain inbound investments, and home-country regimes such as the Investment Canada Act. Most founder-scale software and services deals clear without issue, but the existence and timing of any review should be mapped at the start, not discovered at signing. We scope this with counsel before a process launches so the timeline is realistic.
Yes. U.S. strategics and private equity firms regularly acquire founder-led companies abroad. The process mirrors a domestic sale with added currency, tax-structure, and regulatory layers, all of which are manageable with the right preparation.
Typically five to eight months from launch to close. The added time versus a domestic deal usually comes from cross-border diligence and any regulatory approvals on the back end.
You need an advisor who knows the U.S. buyer universe and can run a U.S.-standard process. That advisor does not have to be U.S.-based; what matters is genuine access to American strategics and sponsors and fluency in both jurisdictions.
Not necessarily. Buyers may apply a discount for cross-border uncertainty, but clean U.S.-legible financials, transferable contracts, and a competitive process close most of that gap, and scarcity can command a premium.
Depending on sector and geography, reviews such as CFIUS in the U.S. or the Investment Canada Act at home. Most founder-scale technology and services deals clear without issue, but timing should be mapped before launch.
Fintech, B2B SaaS, cybersecurity, and AI, the sectors where U.S. acquirers are most active and where we run focused sell-side processes for founder-led companies.
Windsor Drake runs confidential, competitive sale processes for founder-led companies outside the United States. Request a private, no-obligation read on where your business would price today and which buyers are active in your market.
Every inquiry is strictly confidential. Nothing is shared without your written consent.
Receive the research founders read before they sell.
The full research briefing, sent to your inbox. Confidential, no obligation.
